Jeffrey La Rosa
Stock Analyst at Leerink Partners
(0.09)
# 4,127
Out of 4,829 analysts
4
Total ratings
25%
Success rate
-37.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey La Rosa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Outperform | $79 → $91 | $26.08 | +248.99% | 2 | Dec 3, 2024 | |
| PYXS Pyxis Oncology | Initiates: Outperform | $12 | $1.15 | +943.48% | 1 | Jan 23, 2024 | |
| MRK Merck & Co. | Maintains: Outperform | $110 → $112 | $80.43 | +39.25% | 1 | Oct 28, 2022 |
Janux Therapeutics
Dec 3, 2024
Maintains: Outperform
Price Target: $79 → $91
Current: $26.08
Upside: +248.99%
Pyxis Oncology
Jan 23, 2024
Initiates: Outperform
Price Target: $12
Current: $1.15
Upside: +943.48%
Merck & Co.
Oct 28, 2022
Maintains: Outperform
Price Target: $110 → $112
Current: $80.43
Upside: +39.25%